Market news
The average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in Silence Therapeutics (SLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tipranks Press Release.
Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.
Silence Therapeutics (SLN) priced an offering in the US of almost 13 million American depositary sha
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
If divesiran reaches the PV market, it could become the first siRNA therapy for the indication currently dominated by Jakafi and Besremi.
LONDON, August 12, 2026--Silence Therapeutics plc ("Silence" or the "Company") , a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS. In addition, Silence
Silence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company’s plan to advance a quarterly dosing regimen into Phase III.
Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera. Phase 3 trial planned for 1H 2027.
LONDON, August 10, 2026--Silence Therapeutics plc ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States. The proposed offering is a public offering registered under the
LONDON, August 10, 2026--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026.
LONDON, August 09, 2026--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT.
Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.
Silence Therapeutics (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
This is the newest page. Registered accounts read further back.